How to choose a stem cell provider in Tokyo: registration, doctors, cell quality, and follow-up

Many people naturally start by asking which place is best, then the price, then reputation and environment. From a medical perspective, a professional institution won’t follow that sequence, because medicine must first answer “is it appropriate to do,” not “what can be done.”

Even with the same knee issue, there are different situations: early degeneration, structural injury, postoperative recovery, chronic inflammation, etc. Whether a provider pushes a package first, or is willing to review records and imaging, clarify medical history, and judge indications—this alone says a lot. True professionalism is not about fast answers, but accurate judgment.

Stem cell treatment shows clear individual variability. Some people are suitable to consider it; some need to be more cautious. Some aim for improvement and slowing progression; some should not set overly high expectations. In some cases, stem cells shouldn’t be a priority option. These aren’t “pleasant” points, but they best reflect professionalism.

Ultimately, the key to stem cell treatment lies with the doctor: whether they understand cell culture and application, know the differences and risks among protocols, and lead key decisions throughout. During consultation, you can ask directly:

In Japan, regenerative medicine isn’t something an institution can offer at will. For treatments using autologous stem cells, institutions must submit a provision plan under the Act on the Safety of Regenerative Medicine and have it reviewed by a committee; providing care without completing procedures is illegal.

Verification is simple: ask the institution for the treatment name and plan number, then find the institution in the MHLW e-Regenerative Medicine public list and confirm that the treatment name and review committee match what the institution says. See this site’s “How to check a Japanese institution’s regenerative medicine registration” for the steps. Note that registration shows it is under statutory oversight; it does not mean the government recognizes efficacy.

Numbers are the easiest to remember in conversations: how many cells, how many sessions, how long. But quantity is only one parameter; you also need to look at cell status and viability, and whether there are supporting test data.

Whether cells are used after cryopreservation or directly after culture, each has its own process requirements; this alone does not equate to “safer” or “more effective.” Worth asking: what release tests are performed, what viability standard is required, and whether results can be provided in writing.

Some institutions have an in-house CPC; others outsource to specialized external companies. Both approaches can operate compliantly. In-house processing lets doctors directly grasp the process; with external processing, look at how transport time and temperature are ensured.

In either case, you should verify: whether the processing facility has filed registration or obtained a license, its quality management system, transport validation, release criteria, and how responsibility is allocated between the hospital and the processor if problems occur.

Professionalism often shows before and after treatment: whether there is a sufficient initial evaluation, complete explanations and informed consent, monitoring by doctors and nurses before and after infusion or injection, and regular follow-up after treatment.

For overseas patients, post-return follow-up is especially important: how often to report status, by what method, and whom to contact if unwell. Institutions that can explain this clearly and put it in writing are more trustworthy.

Phrases like “hidden champion,” “cannot be replicated,” and “most advanced” are marketing judgments and cannot be verified. More reliable are things that can be found and written down: public registrations and qualifications, names and CVs of responsible doctors, quality test records, and periodic reports.

When we compare Tokyo institutions, we also prioritize information that can be verified. Take Ginza YR Clinic as an example: its Class II and Class III plans and in-house cell processing registrations can all be checked in official lists (this site has a cooperative relationship with this clinic; see “About us” for details).